Study examines safety, immune response of candidate Ebola vaccines

(The JAMA Network Journals) In a study appearing in the April 19, 2016 issue of JAMA, Matthew D. Snape, F.R.C.P.C.H., M.D., of the University of Oxford, United Kingdom, and colleagues conducted a phase 1 trial to evaluate the tolerability and immunogenicity of two candidate Ebola vaccines, an adenovirus type 26 vector vaccine (Ad26.ZEBOV), and a modified Ankara vector vaccine (MVA-BN-Filo).
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news